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The problem of the selection of accurate
primary end-points for treatment studies
in idiopathic pulmonary fibrosis (IPF) has
recently been aired in a controversial
paper from the USA.1 The limitations of
current end-points are discussed and the
authors conclude that all-cause mortality
and all-cause nonelective hospitalisation
best meet clinically meaningful end-point
criteria. Much of the article is well argued
and there is no quarrel with the view that
current primary end-points are flawed. We
also agree that all-cause mortality would,
indeed, be the most clinically meaningful
primary end-point and, therefore, the pre-
ferred primary end-point, were it not
impractical, as discussed below. However,
readers of the statement should reflect on
the wise maxim that ‘the best may be the
enemy of the good’. The purpose of our
document is to provide a perspective on
all-cause mortality as a primary end-
point, endorsed by 52 European clinicians
Including the authors (with one absten-
tion), exploring the implications of the
statement by Raghu and colleagues. We
believe strongly that the adoption of the
views of these authors by licensing bodies
—with, by implication, a statistically sig-
nificant mortality benefit a pre-requisite
for drug registration—would set back
progress in the treatment of IPF by a
decade or more.
It should be acknowledged at the outset
that the statement of Raghu and collea-
gues does not make explicit recommenda-
tions with regard to drug licensing. Indeed,
the authors declare that it is not their aim
to make such recommendations and their
intentions in this regard should not be
questioned. However, if the statement has,
indeed, been widely ‘misread’, the reasons
for this are clear enough. Representatives
of the US Food and Drug Administration
(FDA) were active participants in a forum
in Bethesda, Maryland ( July 2011) which
gave rise to the document as a proceedings
statement.1 It is widely known that if
current phase three studies (of either pirfe-
nidone or nintedanib (BIBF 1120)) show a
positive treatment effect on serial change
in forced vital capacity (FVC), registration
applications will follow in the near future.
As recently as a year ago, all but two of
the authors endorsed the view that in IPF
‘a change in absolute FVC of 10% … is a
surrogate marker of mortality and is evi-
dence of, in the absence of an alternative
explanation, disease progression’.2 Given
the apparent volte-face in the current
document, the timing of the statement
and the participation by FDA personnel,
there is a genuine risk that the registration
process will, indeed, be influenced.
The heart of the matter is the stated
view that because a phase three IPF study
(the INSPIRE study) provided mortality
non-efficacy signal within a realistic inter-
val,3 and significant mortality differences
were observed in another phase three IPF
study (the PANTHER study),4 treatment
trials with mortality as a primary end-
point are, in general, feasible. The same
conclusion might, in principle, be drawn
from findings in the recently published
placebo-controlled evaluation of warfarin
therapy in IPF,5 in which active treatment
was associated with a statistically signifi-
cant increase in mortality.
However, the fatal flaw in this reason-
ing is the fact that in none of these
studies was efficacy demonstrated. In the
PANTHER and warfarin studies, an early
adverse effect was observed which, in the
PANTHER study, appeared to be largely
confined to the first 4 months of treat-
ment. Although the numbers of deaths
in both studies were low (an expected
consequence of the short study duration),
the proportionate increase in mortality
was striking, when compared with the
placebo arm. From these observations it
can be concluded that if a striking early
harmful effect is associated with a
studied intervention, an early mortality
signal should, indeed, be expected. It
appears intrinsically likely that a placebo-
controlled trial of cyanide therapy in IPF
would deliver an early and definitive
result. If there is an obvious lack of effi-
cacy, as in the INSPIRE study, a longer
study period will be required but a con-
clusion based on mortality data can be
anticipated in a realistically short time
interval (provided that studies are
powered for a major and possibly unreal-
istic reduction in mortality).
However, when treatment efficacy (as
opposed to futility or harm) is consid-
ered, a very different picture emerges.
The problem, here, is the consistently
low mortality rate in placebo arms of
recent treatment studies, possibly due in
part to the selective enrolment of
patients with less progressive disease in
placebo-controlled trials. A 25% reduction
in mortality would be widely regarded as
a major treatment benefit, given the like-
lihood that treatment advances in IPF
will consist of small incremental benefits.
It has been estimated, based on the
observed mortality in the recent placebo
arms of IPF studies, that for a 25% reduc-
tion in mortality to be statistically sig-
nificant in a placebo-controlled IPF trial,
the enrolment of 2600 patients and
5 years of follow-up would be required.6
We believe that the performance of
such a study is impracticable. Currently,
pirfenidone, licensed as an IPF treatment
in Europe, can be prescribed in eight
European countries and is available
through named patient programmes in a
number of others. Anti-oxidant therapy
is also widely prescribed in patients
wishing for active treatment. Based on
the pirfenidone precedent, European
registration of nintedanib is likely to be
pursued, in the event of a positive result
in the current nintedanib phase three
studies. In the USA, enrolment is
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currently underway in a number of inter-
ventional studies. It should be stressed
that the current availability of open treat-
ments and interventional studies con-
trasts greatly with the lack of treatment
alternatives at the time of enrolment in
the INSPIRE study. It is unlikely, given
current opportunities, that patients moti-
vated to take part in IPF treatment
studies, will accept a protocol which
requires a commitment to long-term
treatment, despite obvious progression of
disease (whether due to non-efficacy or
to enrolment in a placebo arm). It is
surely far more probable that when pro-
gression is evident, many patients will
opt for open treatment or enrolment in
an alternative treatment study. Raghu
and colleagues would not countenance
efforts to dissuade patients from seeking
alternatives in the event of obvious treat-
ment failure, but given this fact, a proto-
col requiring lifelong placebo-controlled
treatment seems unrealistic.
Nor can it be expected that useful mor-
tality efficacy data might arise from a
less definitive approach. For example, it
cannot be argued with credibility that
concordant mortality trends should be
required in phase three studies in order to
‘validate’ statistically significant beneficial
treatment effects on other end-points. In
current phase three studies, in which a
harmful treatment effect is not evident, a
very low mortality rate is necessarily
associated with wide CIs. The low
number of deaths dictates that chance
alone is likely to give rise to much larger
proportionate variations in mortality
than, for example, a hoped for 25%
reduction in death rate.
The performance of mortality studies
in advanced IPF might seem to be an
attractive option but this approach, also,
is problematic. Patients enrolled in the
placebo-controlled STEP study of sildena-
fil, an agent with no proven clinically sig-
nificant anti-fibrotic activity, were
considered to have severe IPF.7 The
observed treatment effects on gas transfer
and pO2 levels are widely regarded as
indicative of a beneficial effect on the
pulmonary vessels. However, if so, this
underlines the impact of pulmonary
hypertension in advanced IPF, with a
high likelihood that death from pulmon-
ary hypertension will confound any mor-
tality benefit from an anti-fibrotic agent
in this patient sub-group.
A further concern arising from a
requirement for mortality data for drug
registration in IPF is the likely effect on
evaluation of future novel therapies. The
exponential increase in the last decade in
the number of patients enrolled in trials
of IPF treatments is largely ascribable to
the pharmaco-economic model of drug
development. The USA IPF clinical
research network (IPFnet) should be com-
mended for their admirable work in
examining several currently available
treatments, including warfarin, sildenafil,
anti-oxidant therapy and ‘triple therapy’.
However, the successful introduction of
novel agents demands a level of invest-
ment that lies far beyond the scope of
state-sponsored initiatives. A business
model of drug development is required
for this purpose. A requirement for pro-
longed phase three mortality studies of
large IPF patient populations as a pre-
requisite for drug registration, at an esti-
mated cost of US $250 million,6 would
inevitably deter and might entirely
prevent pharmaceutical companies from
developing novel treatments for IPF.
For all of these reasons, we believe
strongly that serial trends in FVC remain
the preferred primary end-point in treat-
ment studies, as recently argued by an
expert group.8 The limitations of FVC
should be acknowledged. Uncertainties
exist regarding the optimal threshold for
‘significant change’9 and, importantly,
trends in FVC and other objective vari-
ables are not synonymous with changes
in dyspnoea, health status or quality of
life.10–13 All measures of outcome in IPF
are flawed but this truism, stressed by
Raghu et al,1 is equally applicable to
outcome variables used in all other
chronic disorders. The limitations of the
6 min walk test are widely acknowledged
and yet, with its use as a primary end-
point in treatment studies, the thera-
peutic landscape has been transformed in
pulmonary arterial hypertension (PAH).
It is sobering to reflect that, had mortal-
ity data been required for drug registra-
tion, it is highly unlikely that targeted
PAH therapies would now be available.
The same is true in cystic fibrosis (CF),
where mortality has long been aban-
doned as a trial end-point. In IPF, the
advantages of FVC over the 6 min walk
distance and other candidate end-points
include excellent measurement character-
istics and a consistent linkage between
categorical FVC changes and mortal-
ity9 14–19—and, also, other clinically
important variables.19
The view that the prevention of disease
progression is not a worthy primary goal,
in its own right, seems counterintuitive, if
not perverse. We acknowledge that the
use of FVC trends primarily as a surrogate
for mortality (as opposed to a marker of
disease progression) can be questioned.
Raghu and colleagues cite a rigorous defin-
ition by which validation of a surrogate
requires that changes in the surrogate are
associated with subsequent concordant
changes in mortality.20 The concern, here,
for which there is precedence,21 is the pos-
sibility that a treatment might have a
beneficial effect on a surrogate but an
adverse effect on mortality. However, this
possibility is surely best excluded by a
requirement for pharmaceutical compan-
ies to provide long-term open treatment
data, including mortality data, after trial
completion. Although less definitive, this
approach is, at least, possible. Treatment
data, validating surrogates of mortality
against subsequent mortality, exist in
only a handful of diseases with a high
prevalence and are highly unlikely to
emerge in IPF.
In summary, we are vehemently
opposed to the idea that mortality data
should be required for drug registration in
IPF. We view mortality as a highly unsuit-
able primary end-point in phase three
trials: unacceptable to patients and likely
to deter pharmaceutical companies from
developing new IPF therapies. Mortality
data are not required for drug registration,
whether in rare respiratory diseases such
as PAH and CF or in common respiratory
diseases such as lung cancer and chronic
obstructive pulmonary disease, and the
idea that this should be required in IPF is
an offence against natural justice and our
patients.
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